Growth Factors of Liver Cancer Therapeutics Market
Liver cancer, particularly hepatocellular carcinoma (HCC), is a leading cause of cancer-related mortality worldwide. The global liver cancer therapeutics market has experienced significant growth in recent years, driven by advancements in treatment options, increasing disease prevalence, and ongoing research and development efforts.
Market Overview
According to a report by Fortune Business Insights, the global liver cancer therapeutics market was valued at approximately USD 1.73 billion in 2019 and is projected to reach USD 7.38 billion by 2027, exhibiting a compound annual growth rate (CAGR) of 20.2% during the forecast period.
Key Factors Driving Market Growth
1. Rising Incidence of Liver Cancer: The increasing prevalence of liver cancer, particularly in regions with high rates of hepatitis B and C infections, is a significant driver of market growth.
2. Advancements in Treatment Modalities: The development of targeted therapies and immunotherapies has revolutionized the treatment landscape for liver cancer, offering more effective and personalized treatment options.
3. Government Initiatives and Funding: Increased government funding for cancer research and initiatives to improve healthcare infrastructure have contributed to the growth of the liver cancer therapeutics market.
Market Segmentation
The liver cancer therapeutics market can be segmented based on therapy type, distribution channel, and region.
By Therapy Type:
Targeted Drug Therapy: These therapies focus on specific molecules involved in cancer cell growth and survival, offering more precise treatment options.
Immunotherapy: Utilizes the body's immune system to fight cancer cells, showing promising results in clinical trials.
Chemotherapy: Traditional treatment that uses drugs to kill rapidly dividing cells, including cancer cells.techsciresearch.com
By Distribution Channel:
Hospital Pharmacy: Hospitals remain the primary point of distribution for liver cancer therapeutics.
Retail Pharmacy: Increasing access to medications through retail pharmacies is expanding treatment availability.
Online Pharmacy: The rise of online pharmacies is improving access to medications, especially in remote areas.
By Region:
North America: Dominated the market with a share of 63.91% in 2019, driven by advanced healthcare infrastructure and high treatment adoption rates.
Europe: Second-largest market, with increasing adoption of advanced therapies.
Asia-Pacific: Expected to witness the highest growth rate due to rising incidence rates and improving healthcare infrastructure.
Challenges and Opportunities
While the liver cancer therapeutics market presents significant growth opportunities, it also faces challenges such as high treatment costs, limited access to advanced therapies in low-resource settings, and the need for early detection methods. However, ongoing research and development efforts, along with collaborations between public and private sectors, are expected to address these challenges and further drive market growth.
Conclusion
The liver cancer therapeutics market is poised for substantial growth, driven by advancements in treatment options, increasing disease prevalence, and ongoing research and development efforts. As the global healthcare landscape continues to evolve, the liver cancer therapeutics market is expected to play a pivotal role in improving patient outcomes and reducing the global burden of liver cancer.
ATTRIBUTES DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD Million)
Segmentation
By Therapy Type
Targeted Drug Therapy
Immunotherapy
Chemotherapy
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America (Therapy Type; Distribution Channel; and Region)
USA (By Therapy Type)
Canada (By Therapy Type)
Europe (Therapy Type; Distribution Channel; and Region)
UK (By Therapy Type)
Germany (By Therapy Type)
France (By Therapy Type)
Italy (By Therapy Type)
Spain (By Therapy Type)
Scandinavia (By Therapy Type)
Rest of Europe (By Therapy Type)
Asia Pacific (Therapy Type; Distribution Channel; and Region)
Japan (By Therapy Type)
China (By Therapy Type)
India (By Therapy Type)
Australia (By Therapy Type)
Southeast Asia (By Therapy Type)
Rest of Asia Pacific (By Therapy Type)
Latin America (Therapy Type; Distribution Channel; and Region)
Brazil (By Therapy Type)
Mexico (By Therapy Type)
Rest of Latin America (By Therapy Type)
Middle East & Africa (Therapy Type; Distribution Channel; and Region)
GCC (By Therapy Type)
South Africa (By Therapy Type)
Rest of MEA (By Therapy Type)
Please Note:
It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Liver Cancer –Key Regions/Country
- 4.2. New Product Launch
- 4.3. Pipeline Analysis
- 4.4. Impact of COVID-19 on the Liver Cancer Treatment Market
- 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
- 5. Global Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Therapy Type
- 5.2.1. Targeted Drug Therapy
- 5.2.2. Immunotherapy
- 5.2.3. Chemotherapy
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacy
- 5.3.2. Retail Pharmacy
- 5.3.3. Online Pharmacy
- 5.4. Market Analysis, Insights and Forecast – By Geography
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Therapy Type
- 6.2.1. Targeted Drug Therapy
- 6.2.2. Immunotherapy
- 6.2.3. Chemotherapy
- 6.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.3.1. Hospital Pharmacy
- 6.3.2. Retail Pharmacy
- 6.3.3. Online Pharmacy
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.1.1. By Therapy Type
- 6.4.1.1.1. Targeted Drug Therapy
- 6.4.1.1.2. Immunotherapy
- 6.4.1.1.3. Chemotherapy
- 6.4.2. Canada
- 6.4.2.1. By Therapy Type
- 6.4.2.1.1. Targeted Drug Therapy
- 6.4.2.1.2. Immunotherapy
- 6.4.2.1.3. Chemotherapy
- 7. Europe Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Therapy Type
- 7.2.1. Targeted Drug Therapy
- 7.2.2. Immunotherapy
- 7.2.3. Chemotherapy
- 7.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.3.1. Hospital Pharmacy
- 7.3.2. Retail Pharmacy
- 7.3.3. Online Pharmacy
- 7.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.4.1. U.K.
- 7.4.1.1. By Therapy Type
- 7.4.1.1.1. Targeted Drug Therapy
- 7.4.1.1.2. Immunotherapy
- 7.4.1.1.3. Chemotherapy
- 7.4.2. Germany
- 7.4.2.1. By Therapy Type
- 7.4.2.1.1. Targeted Drug Therapy
- 7.4.2.1.2. Immunotherapy
- 7.4.2.1.3. Chemotherapy
- 7.4.3. France
- 7.4.3.1. By Therapy Type
- 7.4.3.1.1. Targeted Drug Therapy
- 7.4.3.1.2. Immunotherapy
- 7.4.3.1.3. Chemotherapy
- 7.4.4. Spain
- 7.4.4.1. By Therapy Type
- 7.4.4.1.1. Targeted Drug Therapy
- 7.4.4.1.2. Immunotherapy
- 7.4.4.1.3. Chemotherapy
- 7.4.5. Italy
- 7.4.5.1. By Therapy Type
- 7.4.5.1.1. Targeted Drug Therapy
- 7.4.5.1.2. Immunotherapy
- 7.4.5.1.3. Chemotherapy
- 7.4.6. Scandinavia
- 7.4.6.1. By Therapy Type
- 7.4.6.1.1. Targeted Drug Therapy
- 7.4.6.1.2. Immunotherapy
- 7.4.6.1.3. Chemotherapy
- 7.4.7. Rest of Europe
- 7.4.7.1. By Therapy Type
- 7.4.7.1.1. Targeted Drug Therapy
- 7.4.7.1.2. Immunotherapy
- 7.4.7.1.3. Chemotherapy
- 8. Asia Pacific Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Therapy Type
- 8.2.1. Targeted Drug Therapy
- 8.2.2. Immunotherapy
- 8.2.3. Chemotherapy
- 8.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.3.1. Hospital Pharmacy
- 8.3.2. Retail Pharmacy
- 8.3.3. Online Pharmacy
- 8.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.4.1. Japan
- 8.4.1.1. By Therapy Type
- 8.4.1.1.1. Targeted Drug Therapy
- 8.4.1.1.2. Immunotherapy
- 8.4.1.1.3. Chemotherapy
- 8.4.2. China
- 8.4.2.1. By Therapy Type
- 8.4.2.1.1. Targeted Drug Therapy
- 8.4.2.1.2. Immunotherapy
- 8.4.2.1.3. Chemotherapy
- 8.4.3. India
- 8.4.3.1. By Therapy Type
- 8.4.3.1.1. Targeted Drug Therapy
- 8.4.3.1.2. Immunotherapy
- 8.4.3.1.3. Chemotherapy
- 8.4.4. Australia
- 8.4.4.1. By Therapy Type
- 8.4.4.1.1. Targeted Drug Therapy
- 8.4.4.1.2. Immunotherapy
- 8.4.4.1.3. Chemotherapy
- 8.4.5. Southeast Asia
- 8.4.5.1. By Therapy Type
- 8.4.5.1.1. Targeted Drug Therapy
- 8.4.5.1.2. Immunotherapy
- 8.4.5.1.3. Chemotherapy
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Therapy Type
- 8.4.6.1.1. Targeted Drug Therapy
- 8.4.6.1.2. Immunotherapy
- 8.4.6.1.3. Chemotherapy
- 9. Latin America Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Therapy Type
- 9.2.1. Targeted Drug Therapy
- 9.2.2. Immunotherapy
- 9.2.3. Chemotherapy
- 9.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail Pharmacy
- 9.3.3. Online Pharmacy
- 9.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.4.1. Brazil
- 9.4.1.1. By Therapy Type
- 9.4.1.1.1. Targeted Drug Therapy
- 9.4.1.1.2. Immunotherapy
- 9.4.1.1.3. Chemotherapy
- 9.4.2. Mexico
- 9.4.2.1. By Therapy Type
- 9.4.2.1.1. Targeted Drug Therapy
- 9.4.2.1.2. Immunotherapy
- 9.4.2.1.3. Chemotherapy
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Therapy Type
- 9.4.3.1.1. Targeted Drug Therapy
- 9.4.3.1.2. Immunotherapy
- 9.4.3.1.3. Chemotherapy
- 10. Middle East & Africa Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Therapy Type
- 10.2.1. Targeted Drug Therapy
- 10.2.2. Immunotherapy
- 10.2.3. Chemotherapy
- 10.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.3.1. Hospital Pharmacy
- 10.3.2. Retail Pharmacy
- 10.3.3. Online Pharmacy
- 10.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.4.1. GCC
- 10.4.1.1. By Therapy Type
- 10.4.1.1.1. Targeted Drug Therapy
- 10.4.1.1.2. Immunotherapy
- 10.4.1.1.3. Chemotherapy
- 10.4.2. South Africa
- 10.4.2.1. By Therapy Type
- 10.4.2.1.1. Targeted Drug Therapy
- 10.4.2.1.2. Immunotherapy
- 10.4.2.1.3. Chemotherapy
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Therapy Type
- 10.4.3.1.1. Targeted Drug Therapy
- 10.4.3.1.2. Immunotherapy
- 10.4.3.1.3. Chemotherapy
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Company Profiles (Overview, Therapy, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 11.3.1. Bayer HealthCare Pharmaceuticals Inc.
- 11.3.1.1. Overview
- 11.3.1.2. Therapy
- 11.3.1.3. SWOT Analysis
- 11.3.1.4. Recent Developments
- 11.3.1.5. Strategies
- 11.3.1.6. Financials (Based on Availability)
- 11.3.2. Bristol-Myers & Squibb Company
- 11.3.2.1. Overview
- 11.3.2.2. Therapy
- 11.3.2.3. SWOT Analysis
- 11.3.2.4. Recent Developments
- 11.3.2.5. Strategies
- 11.3.2.6. Financials (Based on Availability)
- 11.3.3. Pfizer Inc.
- 11.3.3.1. Overview
- 11.3.3.2. Therapy
- 11.3.3.3. SWOT Analysis
- 11.3.3.4. Recent Developments
- 11.3.3.5. Strategies
- 11.3.3.6. Financials (Based on Availability)
- 11.3.4. Exelixis, Inc.
- 11.3.4.1. Overview
- 11.3.4.2. Therapy
- 11.3.4.3. SWOT Analysis
- 11.3.4.4. Recent Developments
- 11.3.4.5. Strategies
- 11.3.4.6. Financials (Based on Availability)
- 11.3.5. Merck Sharp & Dohme Corp.
- 11.3.5.1. Overview
- 11.3.5.2. Therapy
- 11.3.5.3. SWOT Analysis
- 11.3.5.4. Recent Developments
- 11.3.5.5. Strategies
- 11.3.5.6. Financials (Based on Availability)
- 11.3.6. Eisai Inc.
- 11.3.6.1. Overview
- 11.3.6.2. Therapy
- 11.3.6.3. SWOT Analysis
- 11.3.6.4. Recent Developments
- 11.3.6.5. Strategies
- 11.3.6.6. Financials (Based on Availability)
- 11.3.7. Eli Lilly and Company
- 11.3.7.1. Overview
- 11.3.7.2. Therapy
- 11.3.7.3. SWOT Analysis
- 11.3.7.4. Recent Developments
- 11.3.7.5. Strategies
- 11.3.7.6. Financials (Based on Availability)
- 11.3.8. F. Hoffmann-La Roche Ltd
- 11.3.8.1. Overview
- 11.3.8.2. Therapy
- 11.3.8.3. SWOT Analysis
- 11.3.8.4. Recent Developments
- 11.3.8.5. Strategies
- 11.3.8.6. Financials (Based on Availability)
- 11.3.9. Other Prominent Players
- 11.3.9.1. Overview
- 11.3.9.2. Therapy
- 11.3.9.3. SWOT Analysis
- 11.3.9.4. Recent Developments
- 11.3.9.5. Strategies
- 11.3.9.6. Financials (Based on Availability)
- 12. Strategic Recommendations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook